^
Association details:
Biomarker:CARD11 mutation
Cancer:Diffuse Large B Cell Lymphoma
Drug Class:BTK inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

2454 Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas

Published date:
11/04/2020
Excerpt:
CTX-177 was efficacious against ABC-DLBCL and MCL models in vitro and in vivo....In addition, the MALT1 inhibitor showed an anti-tumor effect against CARD11 mutated ABC-DLBCL model, which is resistant to BTK inhibitor.